Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between...

Descripción completa

Detalles Bibliográficos
Autores principales: Au, Lewis, Hatipoglu, Emine, Robert de Massy, Marc, Litchfield, Kevin, Beattie, Gordon, Rowan, Andrew, Schnidrig, Desiree, Thompson, Rachael, Byrne, Fiona, Horswell, Stuart, Fotiadis, Nicos, Hazell, Steve, Nicol, David, Shepherd, Scott T.C., Fendler, Annika, Mason, Robert, Del Rosario, Lyra, Edmonds, Kim, Lingard, Karla, Sarker, Sarah, Mangwende, Mary, Carlyle, Eleanor, Attig, Jan, Joshi, Kroopa, Uddin, Imran, Becker, Pablo D., Sunderland, Mariana Werner, Akarca, Ayse, Puccio, Ignazio, Yang, William W., Lund, Tom, Dhillon, Kim, Vasquez, Marcos Duran, Ghorani, Ehsan, Xu, Hang, Spencer, Charlotte, López, José I., Green, Anna, Mahadeva, Ula, Borg, Elaine, Mitchison, Miriam, Moore, David A., Proctor, Ian, Falzon, Mary, Pickering, Lisa, Furness, Andrew J.S., Reading, James L., Salgado, Roberto, Marafioti, Teresa, Jamal-Hanjani, Mariam, Kassiotis, George, Chain, Benny, Larkin, James, Swanton, Charles, Quezada, Sergio A., Turajlic, Samra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599450/
https://www.ncbi.nlm.nih.gov/pubmed/34715028
http://dx.doi.org/10.1016/j.ccell.2021.10.001

Ejemplares similares

Ejemplares similares